Sarah Kim-McOlash

United States Food and Drug Administration

Also affiliated with Center for Drug Evaluation and Research

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma”.

FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3439

N/A

0.470DataRank · unranked

22 citations

Diana Bradford, Somak Chatterjee, Xiaoxue Li, Stephanie Aungst, Amy M. Skinner +22 more

The juvenile gangliosidoses: A timeline of clinical change

Molecular Genetics and Metabolism Reports(2020)10.1016/j.ymgmr.2020.100676

N/A

0DataRank · unranked

17 citations

Sarah Kim-McOlash, Chester B. Whitley, Jeanine R. Jarnes-Utz, Kelly King

FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA -Mutated Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0883

N/A

0DataRank · unranked

0 citations

Dow-Chung Chi, Sundeep Agrawal, Hee‐Koung Joeng, Sarah Kim-McOlash, Wimolnut Manheng +17 more